Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ACM Research, Inc. (ACMR)
NASDAQInformation TechnologySemiconductorsSnapshot 2026-11-04
$39.31-11.52%
Close 2026-11-05 · 1-day change
NASDAQInformation TechnologySemiconductorsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
3.17 → 3.16 EPS · FY ending Dec 31, 2027 · 4 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 4; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for ACMR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Grow electroplating and panel-level packaging product adoption in Asia | Electroplating and panel-level packaging products gain traction in Asia. | Intact | Decline or stagnation in electroplating and panel packaging orders in 2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk growth business, not a steady compounder, because earnings quality is rated fragile even as recent financial performance is strong. The long-term thesis is intact: revenue growth and product progress support it, but the evidence base has medium confidence.
ACMR is rated cheap versus peers, and the valuation model indicates that expectations sit below its fundamental outlook. The valuation measure recently rose from 24.1 to 35.2, while the priced-in assessment says current fragility is justified rather than unusually concentrated.
Near term, recent execution is strong: second-quarter revenue rose to $292.9 million from $215.4 million a year earlier, and management raised its 2026 revenue outlook to $1.125 billion to $1.175 billion. Product progress also supports the multi-year view, including reported growth in ECP and advanced packaging, though global expansion has limited delivery evidence in the supplied financials. Near-term miss risk is rated quiet, but erratic past surprises and recent peer misses remain risks.
The multi-year thesis hinges on ACMR maintaining its raised 2026 outlook and continuing product ramps. A guidance cut after the recent increase would weaken credibility; rate cuts or steadier results from major technology peers could provide a more supportive sector backdrop. Evidence on global expansion and production capacity remains limited.
For the next 1 to 3 years, ACMR combines strong recent growth and product progress with fragile earnings quality and high risk. The thesis remains intact, but continued delivery against the raised outlook is central. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company expands globally with new facilities and customer deployments. |
| Intact |
| Delays or failures in facility ramp-up or new market deployments during 2026 |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Introduce new product cycles and accelerate R&D adoption | A supporting condition in ACM Research, Inc.'s published investment case. The stated target is Sustain active product launches and customer validations in 2026. | Intact | Significant delays or failures in new product launches or customer adoption in 2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain 2026 revenue growth between 21% and 30% | A primary condition in ACM Research, Inc.'s published investment case. The stated target is >=21% YoY revenue growth in 2026. | Intact | YoY revenue growth falls below 21% in FY26 | Revenue growth: 36.01% FY2026-Q2; GAAP. Published target: >=21% YoY revenue growth in 2026. Annual target cannot be compared with a quarterly or TTM observation. Aug 7, 202636.006073 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “W e are raising our full-year 2026 revenue outloo k for 25% to 30% growth.” “Exhibit 99.1 Outlook AC M has raised its revenue guidance range to $1.125 billion to $1.175 billion fo r fiscal year 2026, from the prior range of $1.08 billion to $1.175 billion.” Revenue was $292.919 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$2.25 → $3.16 · observed estimates
$1.46B → $1.51B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-07-25 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-07-26 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-07-27 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-07-28 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-07-29 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-07-30 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-07-31 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-08-01 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-08-02 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-08-03 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-08-04 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-08-05 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-08-06 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-08-07 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-08-08 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-08-09 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-08-10 | $2.25 | $1,455,226,050 | 3 / 7 |
| 2026-08-11 | $2.50 | $1,459,783,190 | 3 / 7 |
| 2026-08-12 | $2.50 | $1,459,783,190 | 3 / 7 |
| 2026-08-13 | $2.50 | $1,459,783,190 | 3 / 7 |
| 2026-08-14 | $2.86 | $1,436,689,922 | 3 / 5 |
| 2026-08-15 | $2.86 | $1,436,689,922 | 3 / 5 |
| 2026-08-16 | $2.86 | $1,436,689,922 | 3 / 5 |
| 2026-08-17 | $2.86 | $1,436,689,922 | 3 / 5 |
| 2026-08-18 | $2.86 | $1,436,689,922 | 3 / 5 |
| 2026-08-19 | $2.86 | $1,436,689,922 | 3 / 5 |
| 2026-08-20 | $3.20 | $1,505,795,204 | 3 / 5 |
| 2026-08-21 | $3.20 | $1,505,795,204 | 3 / 5 |
| 2026-08-22 | $3.20 | $1,505,795,204 | 3 / 5 |
| 2026-08-23 | $3.20 | $1,505,795,204 | 3 / 5 |
| 2026-08-24 | $3.20 | $1,505,795,204 | 3 / 5 |
| 2026-08-25 | $3.20 | $1,505,795,204 | 3 / 5 |
| 2026-08-26 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-08-27 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-08-28 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-08-29 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-08-30 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-08-31 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-01 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-02 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-03 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-04 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-05 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-06 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-07 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-08 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-09 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-10 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-11 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-12 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-13 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-14 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-15 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-16 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-17 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-18 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-19 | $3.23 | $1,514,570,804 | 3 / 6 |
| 2026-09-20 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-09-21 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-09-22 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-09-23 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-09-24 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-09-25 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-09-26 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-09-27 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-09-28 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-09-29 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-09-30 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-10-01 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-10-02 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-10-03 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-10-04 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-10-05 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-10-06 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-10-07 | $3.17 | $1,514,570,804 | 3 / 6 |
| 2026-10-08 | $3.16 | $1,511,840,714 | 3 / 6 |
| 2026-10-09 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-10 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-11 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-12 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-13 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-14 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-15 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-16 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-17 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-18 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-19 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-20 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-21 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-22 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-23 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-24 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-25 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-26 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-27 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-28 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-29 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-30 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-10-31 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-11-01 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-11-02 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-11-03 | $3.16 | $1,511,840,714 | 4 / 7 |
| 2026-11-04 | $3.16 | $1,511,840,714 | 4 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 9 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.